EyePoint Pharmaceuticals appointed John Weet, PhD, as its new senior vice president of regulatory affairs and quality.
Here are three things to know about Dr. Weet:
1. Dr. Weet has over 40 years of experience in regulatory affairs, including oversight of U.S. Food and Drug Administration relations in the area of ocular disease.
2. Previously, he served as the vice president of regulatory affairs and quality assurance at Collegium Pharmaceutical, and as the vice president of global regulatory affairs at Bausch + Lomb.
3. At Bausch + Lomb, Dr. Weet worked on the regulatory submission for Besivance, a drug for the treatment of bacterial conjunctivitis.